CellCentric raised $220 million in a Series D round to advance an oral multiple myeloma therapy into late-stage development. The company said the capital is intended to complete a Phase 2 study and support planning for a Phase 3 trial, with an eye toward taking the drug to market for patients who have exhausted prior options. The round also underscores how investors remain willing to fund clinical programs positioned for later-line differentiation in oncology, particularly where oral administration and a broader patient address could shift treatment patterns.